Compare Davita Inc (DVA) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Manchester United PLC — how do they compare? Davita Inc trades at $229.36 (market cap $14.92B), while Manchester United PLC trades at $22.49 (market cap $3.80B). The key difference: Davita Inc is far larger — about 3.9× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MANU | |
|---|---|---|
Market Cap | $14.92B | $3.80B |
Sector | Health | Media |
52-Week High | $235.71 | $23.53 |
52-Week Low | $103.87 | $15.10 |
Enterprise Value | $27.47B | $4.72B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Manchester United (MANU) trades at $22.31, up 1.23% today, with a bullish technical signal from moving averages. Recent quarterly earnings show mixed results, beating expectations in two of the last four quarters. The company reported a net loss of $33.02 million for 2025, though revenue grew to $666.51 million. Positive developments include securing land for a new 100,000-seat stadium and Champions League qualification, which may boost future revenue.
The outlook is cautiously optimistic with 40% of analysts rating the stock a buy, but high debt levels and inconsistent profitability pose risks. Upside potential exists from stadium development and improved sporting performance, while investor sentiment is supported by institutional interest and strategic partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
